Skip to main content
Top
Published in: Diabetes Therapy 2/2019

Open Access 01-04-2019 | Insulins | Original Research

Effect of Remote Glucose Monitoring Utilizing Computerized Insulin Dose Adjustment Algorithms: A Pilot Project

Authors: Mayer B. Davidson, S. Joshua Davidson

Published in: Diabetes Therapy | Issue 2/2019

Login to get access

Abstract

Introduction

Primary care physicians are often challenged to adjust insulin doses. To facilitate this process, we evaluated in a safety net clinic the work flow and glycemic effects of remote glucose monitoring utilizing Federal Drug Administration (FDA) cleared, Conformité Européenne (CE) registered software that contained computerized algorithms for insulin dose adjustments to help clinicians make dosing decisions for insulin-requiring patients.

Methods

Patients taking insulin for at least 6 months with HbA1c levels of at least 8.0% measured glucose levels with a meter attached to their smartphones. Readings were automatically transmitted to a secure, Health Insurance Portability and Accountability Act (HIPAA)-approved server. Values were analyzed every 2–3 weeks and reports, including recommendations for insulin dose changes, were sent to a clinic nurse practitioner (NP) who modified or accepted the recommendations. A staff person contacted patients with the new doses determined by the NP.

Results

Insulin regimens included basal alone (N = 11), basal/bolus (N = 14), and self-mixed/split (N = 3). Baseline HbA1 levels of 10.0% fell to 8.1% at 3 months (N = 28) and 7.6% at 6 months (N = 17) without any clinic visits for dose adjustments. There were 268 reports which allowed providers to see 268 other patients during these avoided clinic visits. The NP agreed with 82% of the recommendations. The total doses of insulin increased by 24%. No patient experienced severe hypoglycemia or visited an emergency department for hypoglycemia.

Conclusion

Remote glucose monitoring utilizing computerized insulin dose adjustment algorithms saved time for both providers and patients while effectively improving glycemia.

Funding

The Leonard M. Lipman Charitable Trust and Mellitus Health.
Appendix
Available only for authorised users
Literature
1.
go back to reference U.K. Prospective Diabetes Study Group. Overview of 6 years’ therapy of type II diabetes: a progressive disease. Diabetes. 1995;44:1249–58.CrossRef U.K. Prospective Diabetes Study Group. Overview of 6 years’ therapy of type II diabetes: a progressive disease. Diabetes. 1995;44:1249–58.CrossRef
2.
go back to reference Holman RR. Assessing the potential for α-glucosidase inhibitors in prediabetic states. Diabetes Res Clin Pract. 1998;40(Suppl):S21–5.PubMedCrossRef Holman RR. Assessing the potential for α-glucosidase inhibitors in prediabetic states. Diabetes Res Clin Pract. 1998;40(Suppl):S21–5.PubMedCrossRef
3.
go back to reference Selvin E, Porrinello CM, et al. Trends in insulin use and diabetes control in the U.S.: 1988–1994 and 1999–2012. Diabetes Care. 2016;39:e33–5.PubMedCrossRef Selvin E, Porrinello CM, et al. Trends in insulin use and diabetes control in the U.S.: 1988–1994 and 1999–2012. Diabetes Care. 2016;39:e33–5.PubMedCrossRef
4.
5.
go back to reference Jeavons D, Hungin APS, Cornford CS. Patients with poorly controlled diabetes in primary care: healthcare clinicians’ beliefs and attitudes. Postgrad Med J. 2006;82:347–50.PubMedPubMedCentralCrossRef Jeavons D, Hungin APS, Cornford CS. Patients with poorly controlled diabetes in primary care: healthcare clinicians’ beliefs and attitudes. Postgrad Med J. 2006;82:347–50.PubMedPubMedCentralCrossRef
6.
go back to reference Meece J. Dispelling myths and removing barriers about insulin in type 2 diabetes. Diabetes Educ. 2006;32:1342–9.CrossRef Meece J. Dispelling myths and removing barriers about insulin in type 2 diabetes. Diabetes Educ. 2006;32:1342–9.CrossRef
7.
go back to reference Cuddihy RM, Philis-Tsimikas A, Nazeri A. Type 2 diabetes care and insulin intensification: is a more multidisciplinary approach needed? Results from the MODIFY survey. Diabetes Educ. 2011;37:111–23.PubMedCrossRef Cuddihy RM, Philis-Tsimikas A, Nazeri A. Type 2 diabetes care and insulin intensification: is a more multidisciplinary approach needed? Results from the MODIFY survey. Diabetes Educ. 2011;37:111–23.PubMedCrossRef
8.
go back to reference Patrick AR, Fischer MA, Choudry NK, et al. Trends in insulin initiation and treatment intensification among patients with type 2 diabetes. J Gen Intern Med. 2013;29:320–7.PubMedPubMedCentralCrossRef Patrick AR, Fischer MA, Choudry NK, et al. Trends in insulin initiation and treatment intensification among patients with type 2 diabetes. J Gen Intern Med. 2013;29:320–7.PubMedPubMedCentralCrossRef
9.
go back to reference Khunti K, Nikolajsen A, Thorsted BL, Andersen M, Davies MJ, Paul SK. Clinical inertia with regard to intensifying therapy in people with type 2 diabetes treated with basal insulin. Diabetes Obes Metab. 2016;18:401–9.PubMedPubMedCentralCrossRef Khunti K, Nikolajsen A, Thorsted BL, Andersen M, Davies MJ, Paul SK. Clinical inertia with regard to intensifying therapy in people with type 2 diabetes treated with basal insulin. Diabetes Obes Metab. 2016;18:401–9.PubMedPubMedCentralCrossRef
10.
go back to reference Ascher-Svanum H, Lage M, et al. Early discontinuation and restart of insulin in the treatment of type 2 diabetes mellitus. Diabetes Ther. 2014;5:225–42.PubMedPubMedCentralCrossRef Ascher-Svanum H, Lage M, et al. Early discontinuation and restart of insulin in the treatment of type 2 diabetes mellitus. Diabetes Ther. 2014;5:225–42.PubMedPubMedCentralCrossRef
12.
go back to reference Mata-Cases M, Franch-Nadal J, Real J, et al. Therapeutic inertia in patients treated with two or more antidiabetics in primary care: factors predicting intensification of treatment. Diabetes Obes Metab. 2018;20:103–12.PubMedCrossRef Mata-Cases M, Franch-Nadal J, Real J, et al. Therapeutic inertia in patients treated with two or more antidiabetics in primary care: factors predicting intensification of treatment. Diabetes Obes Metab. 2018;20:103–12.PubMedCrossRef
15.
go back to reference Bashan E, Herman WH, Hodish I. Are glucose readings sufficient to adjust insulin dosage? Diabetes Tech Therap. 2011;13:85–92.CrossRef Bashan E, Herman WH, Hodish I. Are glucose readings sufficient to adjust insulin dosage? Diabetes Tech Therap. 2011;13:85–92.CrossRef
16.
go back to reference Davidson MB, Hsia S. Glycemia. In: Meeting the American Diabetes Association standards of care: an algorithmic approach to clinical care of the diabetes patient. American Diabetes Association, Alexandria, VA, 2017, pp. 76–91. Davidson MB, Hsia S. Glycemia. In: Meeting the American Diabetes Association standards of care: an algorithmic approach to clinical care of the diabetes patient. American Diabetes Association, Alexandria, VA, 2017, pp. 76–91.
18.
go back to reference Food and Drug Administration (FDA). Regulation Number 21 CFR 868 1890: Submission # k160673. Food and Drug Administration (FDA). Regulation Number 21 CFR 868 1890: Submission # k160673.
19.
go back to reference Medicines & Healthcare Products Regulatory Agency (MHRA), Reference CA015516. Medicines & Healthcare Products Regulatory Agency (MHRA), Reference CA015516.
20.
go back to reference Davidson MB, Lewis G. Effect of data management on a central server on HbA1c levels in insulin-requiring patients. Diabetes Care. 2000;23:706–7.PubMedCrossRef Davidson MB, Lewis G. Effect of data management on a central server on HbA1c levels in insulin-requiring patients. Diabetes Care. 2000;23:706–7.PubMedCrossRef
21.
go back to reference Davidson MB, Blanco-Castellanos M, Duran P. Integrating nurse-directed diabetes management into a primary care setting. Am J Manag Care. 2010;16:652–6.PubMed Davidson MB, Blanco-Castellanos M, Duran P. Integrating nurse-directed diabetes management into a primary care setting. Am J Manag Care. 2010;16:652–6.PubMed
22.
go back to reference Brazeau AS, Mircescu H, Leroux C, et al. Carbohydrate counting accuracy and blood glucose variability in adults with type 1 diabetes. Diabetes Res Clin Pract. 2013;99:19–23.PubMedCrossRef Brazeau AS, Mircescu H, Leroux C, et al. Carbohydrate counting accuracy and blood glucose variability in adults with type 1 diabetes. Diabetes Res Clin Pract. 2013;99:19–23.PubMedCrossRef
24.
go back to reference Bell KJ, Toschi E, Steil GM, et al. Optimized mealtime insulin dosing for fat and protein in type 1 diabetes: application of a model-based approach to derive insulin doses for open-loop diabetes management. Diabetes Care. 2016;39:1631–4.PubMedCrossRef Bell KJ, Toschi E, Steil GM, et al. Optimized mealtime insulin dosing for fat and protein in type 1 diabetes: application of a model-based approach to derive insulin doses for open-loop diabetes management. Diabetes Care. 2016;39:1631–4.PubMedCrossRef
25.
go back to reference Paterson MA, Smart CEM, Lopez PE, et al. Increasing the protein quantity in a meal results in dose-dependent effects on postprandial glucose levels in individuals with type 1 diabetes mellitus. Diabetic Med. 2017;34:851–4.PubMedCrossRef Paterson MA, Smart CEM, Lopez PE, et al. Increasing the protein quantity in a meal results in dose-dependent effects on postprandial glucose levels in individuals with type 1 diabetes mellitus. Diabetic Med. 2017;34:851–4.PubMedCrossRef
28.
go back to reference Davidson MB. Delayed response to NPH insulin. In: Draznin B, editor. Diabetes case files: real problems, practical solutions. Alexandria: American Diabetes Association; 2014. p. 267–70. Davidson MB. Delayed response to NPH insulin. In: Draznin B, editor. Diabetes case files: real problems, practical solutions. Alexandria: American Diabetes Association; 2014. p. 267–70.
30.
go back to reference Harper R, Donnelly R, Bi Y, et al. Dynamics in insulin requirements and treatment safety. J Diabetes Compl. 2016;30:1333–8.CrossRef Harper R, Donnelly R, Bi Y, et al. Dynamics in insulin requirements and treatment safety. J Diabetes Compl. 2016;30:1333–8.CrossRef
31.
go back to reference Edelman SV, Liu R, Johnson J, Glass LG. AUTONOMY: the first randomized trial comparing two patient-driven approaches to initiate and titrate prandial insulin lispro in type 2 diabetes. Diabetes Care. 2014;37:2132–40.PubMedCrossRef Edelman SV, Liu R, Johnson J, Glass LG. AUTONOMY: the first randomized trial comparing two patient-driven approaches to initiate and titrate prandial insulin lispro in type 2 diabetes. Diabetes Care. 2014;37:2132–40.PubMedCrossRef
32.
33.
go back to reference Calvert MJ, McManis RJ, Freemantle N. Management of type 2 diabetes with multiple oral hyperglycaemic agents or insulin in primary care retrospective cohort study. Br J Gen Pract. 2007;57:455–60.PubMedPubMedCentral Calvert MJ, McManis RJ, Freemantle N. Management of type 2 diabetes with multiple oral hyperglycaemic agents or insulin in primary care retrospective cohort study. Br J Gen Pract. 2007;57:455–60.PubMedPubMedCentral
34.
go back to reference Rubino A, McQuay LJ, Gough SC, et al. Delayed initiation of subcutaneous insulin therapy after failure of oral glucose-lowering agents in patients with type 2 diabetes: a population-based analysis in the UK. Diabet Med. 2007;24:1412–8.PubMedCrossRef Rubino A, McQuay LJ, Gough SC, et al. Delayed initiation of subcutaneous insulin therapy after failure of oral glucose-lowering agents in patients with type 2 diabetes: a population-based analysis in the UK. Diabet Med. 2007;24:1412–8.PubMedCrossRef
35.
go back to reference Nichols GA, Koo YH, Shah SN. Delay of insulin addition to oral combination therapy despite inadequate glycemic control. J Gen Intern Med. 2007;22:453–8.PubMedPubMedCentralCrossRef Nichols GA, Koo YH, Shah SN. Delay of insulin addition to oral combination therapy despite inadequate glycemic control. J Gen Intern Med. 2007;22:453–8.PubMedPubMedCentralCrossRef
36.
go back to reference Khunti K, Wolden MI, Thorsted BL, et al. Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. Diabetes Care. 2013;36:3411–7.PubMedPubMedCentralCrossRef Khunti K, Wolden MI, Thorsted BL, et al. Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. Diabetes Care. 2013;36:3411–7.PubMedPubMedCentralCrossRef
37.
go back to reference Home P, Naggar NE, Khamseh M, et al. An observational non-interventional study of people with diabetes beginning or changed to insulin analogue therapy in non-Western countries: the A1chieve study. Diabetes Res Clin Pract. 2011;94:352–63.PubMedCrossRef Home P, Naggar NE, Khamseh M, et al. An observational non-interventional study of people with diabetes beginning or changed to insulin analogue therapy in non-Western countries: the A1chieve study. Diabetes Res Clin Pract. 2011;94:352–63.PubMedCrossRef
38.
go back to reference Harris SB, Kapor J, Lank CN, et al. Clinical inertia in patients with T2DM requiring insulin in family practice. Can Fam Physician. 2010;56:e418–24.PubMedPubMedCentral Harris SB, Kapor J, Lank CN, et al. Clinical inertia in patients with T2DM requiring insulin in family practice. Can Fam Physician. 2010;56:e418–24.PubMedPubMedCentral
39.
go back to reference Yang Y, Lang Q, Jackson SL, et al. Nurse practitioners, physician assistants, and physicians are comparable in managing the first five years of diabetes. Am J Med. 2018;131:276–83.PubMedCrossRef Yang Y, Lang Q, Jackson SL, et al. Nurse practitioners, physician assistants, and physicians are comparable in managing the first five years of diabetes. Am J Med. 2018;131:276–83.PubMedCrossRef
40.
go back to reference Balkau B, Calvi-Gries F, Freemantle N, Vincent M, Pilorget V, Home PD. Predictors of HbA1c over 4 years in people with type 2 diabetes starting insulin therapies: the CREDIT study. Diabetes Res Clin Pract. 2015;108:432–40.PubMedCrossRef Balkau B, Calvi-Gries F, Freemantle N, Vincent M, Pilorget V, Home PD. Predictors of HbA1c over 4 years in people with type 2 diabetes starting insulin therapies: the CREDIT study. Diabetes Res Clin Pract. 2015;108:432–40.PubMedCrossRef
41.
go back to reference Ziemer DC, Miller CD, Rhee MK, et al. Clinical inertia contributes to poor diabetes control in a primary care setting. Diabetes Educ. 2005;31:564–71.PubMedCrossRef Ziemer DC, Miller CD, Rhee MK, et al. Clinical inertia contributes to poor diabetes control in a primary care setting. Diabetes Educ. 2005;31:564–71.PubMedCrossRef
42.
go back to reference Chen Y, Abbott S, Nguyen M, et al. Glycemic control of insulin treated patients across the U.S.: epidemiologic analysis of a commercially insured population. Diabetes. 2013;62(Suppl 1):A704. Chen Y, Abbott S, Nguyen M, et al. Glycemic control of insulin treated patients across the U.S.: epidemiologic analysis of a commercially insured population. Diabetes. 2013;62(Suppl 1):A704.
43.
go back to reference American Diabetes Association. Economic costs of diabetes in the U.S. in 2017. Diabetes Care. 2018;41:917–28.CrossRef American Diabetes Association. Economic costs of diabetes in the U.S. in 2017. Diabetes Care. 2018;41:917–28.CrossRef
44.
go back to reference The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–86.CrossRef The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–86.CrossRef
45.
go back to reference Gilmer TP, O’Connor PJ, Manning WG, et al. The cost to health plans of poor glycemic control. Diabetes Care. 1997;20:1847–53.PubMedCrossRef Gilmer TP, O’Connor PJ, Manning WG, et al. The cost to health plans of poor glycemic control. Diabetes Care. 1997;20:1847–53.PubMedCrossRef
Metadata
Title
Effect of Remote Glucose Monitoring Utilizing Computerized Insulin Dose Adjustment Algorithms: A Pilot Project
Authors
Mayer B. Davidson
S. Joshua Davidson
Publication date
01-04-2019
Publisher
Springer Healthcare
Published in
Diabetes Therapy / Issue 2/2019
Print ISSN: 1869-6953
Electronic ISSN: 1869-6961
DOI
https://doi.org/10.1007/s13300-019-0565-y

Other articles of this Issue 2/2019

Diabetes Therapy 2/2019 Go to the issue